MCRA, LLC a leading medical device focused regulatory advisory firm and clinical research organization (CRO) integrating U.S. and International Regulatory Affairs, Clinical Trial Operations, Reimbursement and Market Access, Healthcare Compliance, Cybersecurity, and Quality Assurance support is pleased to announce its involvement with successfully obtaining several new CPT codes and payment reassignments on behalf of numerous clients.
Prior to the publication of the rules, MCRA worked with CMS to establish appropriate payment assignment for several clients and received validation of the decisions with the publication of the Final CY 2022 Payment Rules for Medicare Hospital and Physician Payments on November 2, 2021.
In addition, following the September CPT Coding Editorial Panel meeting the AMA published its final decisions validating that MCRA successfully collaborated with its clients and with relevant specialty societies to establish several Category III CPT codes as well as a Category I CPT code, the latter of which required stringent publication requirements and robust utilization data.
Vincent Lesniewski, Senior Director, Market Access, at Centinel Spine said, “Through our collaboration with and guidance from the MCRA reimbursement team, we are pleased to report a successful panel meeting and the issuance of a permanent CPT code that will allow providers to report use of the prodiscL™ technology at two levels”.
Debbie Garner, Co-CEO, of FemSelect said, “We are thrilled with the outcome of our work with the MCRA team to establish appropriate hospital outpatient and ASC payment assignment, allowing for women who suffer from the symptoms of pelvic organ prolapse to access the EnPlace technology.”
Nestor Jaramillo, President and CEO, of Nuwellis said, “With the help of MCRA’s Reimbursement team, Ultrafiltration with Aquadex has realized key reimbursement milestones in 2021, with the successful assignment of a CPT code and a payment assignment in the hospital outpatient setting.”
Tonya Dowd, MCRA’s Vice President of Reimbursement Health Economics and Market Access said, “Establishing new coding mechanisms and appropriate payment assignment is imperative to ensure market access for patients who can benefit from our clients’ innovative therapies. We are delighted that our Reimbursement, Health Economics and Market Access team, collaborated well with the respective organizations to achieve this success for them.”